Anaplastic astrocytoma market seen reaching $0.64 billion by 2030

The global anaplastic astrocytoma market is projected to grow from $0.46 billion in 2025 to $0.64 billion by 2030, according to The Business Research Company. The report points to rising brain tumor incidence, more precision medicine use, and stronger research investment as key drivers.

Why it matters: - Anaplastic astrocytoma is a rare, aggressive brain cancer, so growth in this market points to higher demand for diagnostics, surgery, radiation, chemotherapy and newer oncology treatments. - The forecast also signals more investment in neuro-oncology research and broader use of precision medicine and targeted therapies.

What happened: - The Business Research Company released its Anaplastic Astrocytoma Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the global anaplastic astrocytoma market will rise from $0.46 billion in 2025 to $0.49 billion in 2026. - The market is forecast to reach $0.64 billion by 2030, implying a 7.0% CAGR over the forecast period. - The company also made a free sample report available.

The details: - Historical growth was linked to improved brain tumor diagnostics, wider access to neurosurgery, more oncology treatment centers, increased clinical trial activity and greater use of radiotherapy. - Future growth is expected to come from more funding for neuro-oncology research, adoption of precision medicine, development of targeted and adjunct therapies, earlier detection and stronger collaboration between research groups. - Key market trends include multimodal treatment strategies, advanced neuroimaging, personalized oncology therapies, more clinical research and better coordination between surgery and radiotherapy. - Anaplastic astrocytoma originates from astrocytes, the cells that support the nervous system. - The tumor can cause headaches, seizures, behavioral changes and motor impairments. - Standard treatment combines surgical removal, radiation therapy and chemotherapy. - Rising primary brain tumor incidence is a major growth driver for the market. - In March 2023, the American Society of Clinical Oncology said about 24,810 adults in the U.S. are expected to be diagnosed with primary cancerous tumors of the brain and spinal cord, including 14,280 men and 10,530 women. - North America held the largest market share in 2025, supported by strong healthcare infrastructure and high research investment. - Asia-Pacific is expected to grow fastest during the forecast period because of better healthcare access, rising awareness and expanding medical facilities. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The market remains small in dollar terms, but the growth rate is notable for a rare cancer category. - The report’s emphasis on early detection and precision medicine suggests treatment innovation is becoming as important as volume growth. - North America’s lead and Asia-Pacific’s faster expected growth point to a market that is still concentrated in developed health systems but expanding as access improves.

What's next: - The market will likely keep tracking advances in neuro-oncology, especially targeted treatments, multimodal care and imaging tools. - The report’s forecast suggests research spending and clinical collaboration could shape the next phase of market expansion. - View the full report.